Review Article | Volume: 7, Issue : 4, April, 2017

HAART and Hepatotoxicity

Devaraj Ezhilarasan Mohan Srilekha Ramanathan Raghu   

Open Access   

Published:  Apr 30, 2017

DOI: 10.7324/JAPS.2017.70433

Antiretroviral (ARV) drugs are given in combination to treat the human immunodeficiency virus (HIV) infection and to prolong the life expectancy of the patient. The increase in the levels of hepatotoxicity due to the use of above drugs has been the concern till date. Lactic acidosis, hepatocytes fatty infiltration and oxidative stress are the commonly associated hepatotoxic effects with the administration of nucleoside reverse transcriptase inhibitors. Non-nucleooside reverse transcriptase inhibitors such as nevirapine and efavirenz inhibit bile acid transport causing cholestasis which in turn causes apoptosis to the hepatocytes. Furthermore, hepatitis C and B virus co-infection and Tuberculus bacilli in HIV infected patients remains a vital risk factor for the development of hepatotoxicity associated with highly active antiretroviral therapy (HAART). Overwhelming evidences clearly shows that the ARV drugs mediated hepatotoxicity has been attributed due to their mitochondrial interference. Although a low grade of hepatotoxicity resolves, high levels of toxicity leads to discontinuation of the therapy. Hence, careful observation is necessary especially during and after HAART to study the drug-induced liver diseases.

Keyword:     Zidovudinehepatotoxicityantiretroviral drugsHIV.


Ezhilarasan D, Srilekha S, Raghu R. HAART and Hepatotoxicity. J App Pharm Sci, 2017; 7 (04): 220-226.

Copyright:The Author(s). This is an open access article distributed under the Creative Commons Attribution Non-Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HTML Full Text


Article Metrics

354 Absract views 7 PDF Downloads 361 Total views

   Abstract      Pdf Download

Related Search

By author names

Citiaion Alert By Google Scholar

Name Required
Email Required Invalid Email Address

Comment required